Stock AnalizElevance Health, Inc. ELV
Medical Specialities · data as of November 13, 2026
Elevance Health, Inc. (ELV) is a healthcare company listed in the US with a market value of about $92.8B. In the twelve months to September 30, 2026 it had revenue of $201.8B and net income of $5.1B, a net margin of 2.5%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is shareholder returns (5/5); the weakest is future growth (1/5).
Key numbers: a P/E of 18.3, a price to free cash flow of 14.3, 5-year revenue growth of 10% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 1% above the current price.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
Checks not passed
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.8B | $199.1B | $177.0B | $171.3B | $156.6B | $138.6B | $121.9B | $104.2B | $92.1B | $90.0B | $84.9B |
| Net income | $5.1B | $5.7B | $6.0B | $6.0B | $5.9B | $6.2B | $4.6B | $4.8B | $3.8B | $3.8B | $2.5B |
| Free cash flow | $6.5B | $3.2B | $4.6B | $6.8B | $7.2B | $7.3B | $9.7B | $5.0B | $2.6B | $3.4B | $2.7B |
| EPS (diluted) | $23.52 | $25.21 | $25.68 | $25.22 | $24.28 | $24.95 | $17.98 | $18.47 | $14.19 | $14.35 | $9.21 |
| Net margin | 2.5% | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | 3.8% | 4.6% | 4.1% | 4.3% | 2.9% |
| ROIC | — | 8.0% | 8.1% | 10.2% | 10.5% | 9.7% | 8.6% | 9.4% | 8.6% | 9.0% | 6.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 21 analysts is $482.38, 12% above the current price; targets range from $406.00 to $523.00; the consensus rating is “Buy”; expected EPS is $29.14 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Elevance Health’s P/E ratio?
About 18.3, based on the last twelve months of diluted earnings per share (forward P/E about 14.6).
Is Elevance Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 1% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Elevance Health pay a dividend?
Yes. The dividend yield is about 1.60%, and it has paid dividends for 10 years in our data.
Is Elevance Health a good stock to buy?
We do not give buy or sell advice. Elevance Health scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.